Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  vinblastine sulfate
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-23 of 23 for your search:
Start Over
Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 to 75
Sponsor: Other
Protocol IDs: CGC05MK1002, NCT00188149
Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 17 and under
Sponsor: Other
Protocol IDs: CDR0000667369, EURONET-PHL-LP1, EUDRACT-2007-004092-19, EU-21011, NCT01088750
Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma
Phase: Phase III
Type: Diagnostic, Treatment
Status: Active
Age: 17 and under
Sponsor: Other
Protocol IDs: CDR0000531687, EURONET-PHL-C1, EU-20703, EUDRACT-2006-000995-33, CCLG-HD-2007-10, NCT00433459
Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 16 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: ASI-HDIII 0109, NCT00816959
Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: 2011/119/HP, NCT01812369
Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas
Phase: Phase II
Type: Treatment
Status: Active
Age: 25 and under
Sponsor: Other
Protocol IDs: CDR0000069065, CHP-686, CHP-IRB-2001-2-2339, NCI-V01-1678, NCT00030264
Vinblastine, Cyclophosphamide, Procarbazine, Prednisolone, Etoposide, Mitoxantrone, and Bleomycin in Treating Older Patients With Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: CDR0000354225, UON-SHIELD, EU-20346, NCT00079105
Immunochemotherapy for Metastatic Renal Cell Carcinoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 1747CTIL, Raphael Rubinov, NCT00226798
"Geriatric Assessment Adapted" Therapy for Ph- ALL Elderly Patients
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: LAL1104, NCT00475280
Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: CT/07.16, NCT00635726
Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL)
Phase: Phase II
Type: Diagnostic, Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: GITIL - HD0607, NCT00795613
Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: ASI-HDII 1108, NCT00797472
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: HOD08, NCI-2009-01138, NCT00846742
Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Active
Age: 18 to 60
Sponsor: NCI, Other
Protocol IDs: CALGB-50801, CDR0000669076, NCI-2011-02034, NCT01118026
Prospective Multicentric Evaluation of a Bladder Preservation Strategy
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 69
Sponsor: Other
Protocol IDs: 0908038, 2009-014264-19, NCT01093066
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Active
Age: 18 to 60
Sponsor: NCI, Other
Protocol IDs: CDR0000672913, CALGB-50604, NCT01132807
A Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing soliD Tumours.
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 4 to 21
Sponsor: Other
Protocol IDs: 2010-12, 2010-021792-81, NCT01285817
Prospective Study on HIV-related Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: HIV-HL 2004, NCT01468740
Vinblastine and Temsirolimus in Pediatric Patients With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
Phase: Phase I
Type: Treatment
Status: Approved-not yet active
Age: 1 to 18
Sponsor: Other
Protocol IDs: I218, NCT02343718
Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0810010015, NCT00901303
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 3 at diagnosis
Sponsor: NCI, Other
Protocol IDs: SJYC07, R01CA154619, NCI-2011-01193, SJCRH-SJYC07, NCT00602667
Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: LCCC 1115, NCT01578967
Brentuximab Vedotin Combined With AVD Chemotherapy and Involved-Site Radiotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Phase: No phase specified
Type: Supportive care, Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: 13-034, NCT01868451
Start Over